In this bonus episode of Transforming Healthcare with electronRx, we explore the complexities of interstitial lung disease drawing inspiration from our recent blog.
This umbrella term used to describe a group of highly variable restrictive lung diseases, characterised by inflammation and pulmonary fibrosis.
Treatment options include:
- Corticosteroids: Pfizer, Novartis, GSK, Merck, Astrazeneca
- Bronchodilators: AstraZeneca, GSK
- Antifibrotics: Roche, Boehringer Ingelheim
- Immunosuppressants: Astrellas, Sanofi, Bristol-Myers Squibb, Novartis, Roche
To read the full blog visit electronrx.com
Brought to you by electronRx
Follow us on LinkedIn
